返回 
加入收藏
沙美特罗替卡松联合噻托溴铵不同吸入装置给药治疗慢性阻塞性肺疾病的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 沙美特罗替卡松联合噻托溴铵不同吸入装置给药治疗慢性阻塞性肺疾病的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察沙美特罗替卡松联合噻托溴铵不同吸入装置给药治疗慢性阻塞性肺疾病（COPD）患者的临床疗效和安全性。方法：选择2014年1月－2015年1月我院COPD患者80例，按照随机数字表法分为试验组和对照组，各40例。两组患者均给予沙美特罗替卡松粉吸入剂500 μg，bid+噻托溴铵粉吸入剂18 μg，qd，对照组患者使用药品自带吸入装置给药，试验组患者使用气体压缩式超声雾化吸入器给药。两组患者均治疗1年。观察两组患者给药0.5 h后的血药浓度，给药后第3、6、9个月的呼吸困难指数（mMRC）评分和COPD评估测试（CAT）评分，治疗期内急性加重次数，治疗前后1秒用力呼气容积占预计值的百分比（FEV1％），并记录不良反应发生情况。结果：试验组患者脱落4例，对照组患者脱落1例。给药0.5 h后，两组患者替卡松、沙美特罗和噻托溴铵的血药浓度比较，差异均无统计学意义（P＞0.05）。给药后，试验组患者mMRC评分略低于对照组，但差异无统计学意义（P＞0.05）；CAT评分明显低于对照组，差异有统计学意义（P＜0.05）。试验组患者治疗期间急性加重次数明显少于对照组，差异有统计学意义（P＜0.05）。试验组患者的FEV1％下降值略低于对照组，但差异无统计学意义（P＞0.05）。试验组患者不良反应发生率明显低于对照组，差异有统计学意义（P＜0.05）。结论：沙美特罗替卡松联合噻托溴铵使用气体压缩式超声雾化吸入器给药治疗COPD患者的临床疗效和安全性均优于药品自带吸入装置给药。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy and safety of salmeterol fluticasone combined with tiotropium bromide in the treatment of COPD via different inhalation devices. METHODS： Eighty COPD patients were selected from our hospital during Jan. 2014 to Jan. 2015， and then divided into trial group and control group according to random number table， with 40 cases in each group. Both groups were given Salmeterol fluticasone inhalant 500 μg，bid+Tiotropium bromide inhalant 18 μg，qd. Control group was given medicine via inhalation device coming with medicine， while trial group was given medicine via gas compression type ultrasonic spray inhalator. Both groups were treated for 1 year. Blood concentration of medicine 0.5 h after medication， mMRC score and COPD acsessment test （CAT） score 3， 6， 9 months after treatment， the times of acute exacerbation during treatment， FEV1％ before and after treatment were all observed in 2 groups. The occurrence of ADR was recorded. RESULTS： Four cases withdrew from trial group and 1 case from control group. After medication， there was no statistical significance in blood concentration of fluticasone， salmeterol and tiotropium bromide between 2 groups （P＞0.05）. 0.5 h after medication， mMRC score of trial group was slightly lower than that of control group， without statistical significance （P＞0.05）； CAT score of it was significantly lower than that of control group， with statistical significance （P＜0.05）. The times of acute exacerbation in trial group during treatment was significantly less than control group， with statistical significance （P＜0.05）. The decrease of FEV1％ in trial group was slightly lower than control group， without statistical significance （P＞0.05）. The incidence of ADR in trial group was significantly lower than control group， with statistical significance （P＜0.05）. CONCLUSIONS： For COPD patients， salmeterol fluticasone combined with tiotropium bromide via gas compression type ultrasonic spray inhalator is better than inhalation device coming with medicine in clinical efficacy and safety. |
| 期刊： | 2017年第28卷第8期 |
| 作者： | 朱惠兰，向秀梅，周莉梅，石璐，王飞飞 |
| AUTHORS： | ZHU Huilan，XIANG Xiumei，ZHOU Limei，SHI Lu，WANG Feifei |
| 关键字： | 沙美特罗替卡松；噻托溴铵；吸入装置；慢性阻塞性肺疾病；疗效；安全性 |
| KEYWORDS： | Salmeterol fluticasone； Tiotropium bromide； Inhalation device； COPD； Therapeutic efficacy； Safety |
| 阅读数： | 389 次 |
| 本月下载数： | 7 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
